STAXMAXXX INDEX / LOOK / Clinical

GLP-1 Receptor Agonists

Real drugs. Real evidence. Really prescription-only.

STAXXX evidence grade · GLP-1 Receptor Agonists

STRONG

Consistent human evidence at the highest tiers. This works, within its lane.

  1. STRONG
  2. MODERATE
  3. EMERGING
  4. INSUFFICIENT
Regulatory status
Prescription only
Sources on file
4 total · 3 human · 2 pending
Rubric score
7 weighted
Computed by the published STAXXX rubric · index-rubric.2026-08-15.1

WHAT IT IS

A class of prescription medicines — semaglutide and tirzepatide are the known names — originally developed for type 2 diabetes and now approved for chronic weight management. They are the most effective weight-loss medicines ever brought to market, and they are drugs in every legal and medical sense.

HOW IT WORKS

They mimic GLP-1, a gut hormone released after eating, which slows stomach emptying and acts on appetite circuits in the brain. People feel full sooner and think about food less. The effect is powerful, sustained while on the medicine, and typically reverses when it stops — which is why medical supervision is the entire model, not a formality.

WHERE THE EVIDENCE STANDS

Large randomized trials show double-digit percentage body-weight reduction, and regulatory approval in multiple countries rests on that data. STRONG is the honest grade — and none of that strength transfers to unsupervised, compounded, or gray-market use, which is where the documented harms concentrate.

SOURCES

  • REFERENCERegulatory approval

    FDA approval of semaglutide for chronic weight management

    US Food and Drug Administration · 2021

  • REFERENCERandomized trial

    Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

    New England Journal of Medicine (Wilding et al.) · 2021

  • REFERENCERandomized trialPending document

    Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)

    New England Journal of Medicine (Lincoff et al.) · 2023

  • REFERENCERegulatory statusPending document

    FDA communications on compounded semaglutide products

    US Food and Drug Administration

    Documents adverse-event reports and quality concerns with compounded versions.

2 of 4 documents are not confirmed yet. Pending means pending.

REGULATORY STATUS

Prescription onlyPrescription medicines in every major market. The only legitimate access path is evaluation by a licensed clinician who takes responsibility for the decision, the monitoring, and the source. Compounded and gray-market versions are where the quality and safety failures cluster.

WHO THIS IS FOR

  • People with significant weight to lose who want the honest picture before a clinical conversation
  • Anyone being marketed a compounded shortcut and wondering why it is cheaper

WHAT PEOPLE GET WRONG

The compounded version is the same medicine at a fair price.
Compounded products are not FDA-approved, not verified for content or sterility by the approval system, and are the subject of specific FDA warnings. Same molecule name; not the same assurance.
It replaces training and food quality.
Trial participants received lifestyle support alongside the medicine, and preserving muscle through resistance training while losing weight is a real clinical concern. The drug changes appetite. The physique is still built.

QUESTIONS

Can I get GLP-1 medicines through STAXXX?
No. STAXXX does not sell, source, or recommend prescription medicines. What we do is prepare you for a real clinical conversation and route you to a licensed provider who owns the decision.
Are these medicines actually effective?
Yes — the randomized-trial evidence is among the strongest in modern metabolic medicine. Effectiveness is not the gate. Medical supervision is the gate, because dosing decisions, side-effect management, and sourcing all require a clinician.

Reference only · Not medical advice · No dosing, protocols, or sourcing anywhere in this index · Last reviewed 2026-08-15 · How we grade